Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 133-141

  McDermott, David F ^a   Regan, Meredith M ^a   Clark, Joseph I ^a   Flaherty, Lawrence E ^a   Weiss, Geoffery R ^a   Logan, Theodore F ^a   Kirkwood, John M ^a   Gordon, Michael S ^a   Sosman, Jeffrey A ^a   Ernstoff, Marc S ^a   Tretter, Christopher P G ^a   Urba, Walter J ^a   Smith, John W ^a   Margolin, Kim A ^a   Mier, James W ^a   Gollob, Jared A ^a   Dutcher, Janice P ^a   Atkins, Michael B ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 16644401873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.206     Document Type: Article

References (22)

1. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
2. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant Interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55-S57, 2000
3. Belldegrun A, Webb DE, Austin HA III, et al: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: Effect of pre-therapy nephrectomy. J Urol 141:499-503, 1989
4. Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 7:486-498, 1989
5. Sleijfer DT, Janssen RA, Buter J, et al: Phase Il study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1992
6. Lopez Hanninen E, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996
7. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
8. Atzpodien J, Lopez Hanninen E, Kirchner H, et al: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and Interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501, 1995
9. Figlin RA, Belldegrun A, Moldawer N, et al: Concomitant administration of recombinant human interleukin-2 and recombinant Interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10:414-421, 1992
10. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human Interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
11. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus Interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11:1809-1816, 1993
12. Atzpodien J, Kirchner H, Hanninen EL, et al: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A:S6-S8, 1993 (suppl 5)
13. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with Interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
14. Dutcher JP, Fisher RI, Weiss G, et al: Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: Five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3:157-162, 1997
15. Dutcher JP, Atkins M, Fisher R, et al: Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 1:S73-S78, 1997 (suppl)
16. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
17. Fyfe GA, Fisher RI, Rosenberg SA, et al: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 14:2410-2411, 1996
18. Yang JC, Sherry RM, Steinberg SM, et al: A randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 21:3127-3132, 2003
19. Upton MP, Parker RA, Youmans A, et al: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. Proc Am Soc Clin Oncol 22:851, 2003 (abstr 3420)
20. Bui MHT, Seligson D, Han K, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811, 2003
21. Atkins M, McDermott D, Regan M, et al: Carbonic anhydrase IX expression predicts for renal cancer response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 23:383, 2004 (abstr 4512)
22. Leibovich BC, Han KR, Bui MH, et al: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma stratification tool for prospective clinical trials. Cancer 98:2566-2575, 2003